SLC5A2 and chronic kidney disease: Although new therapeutic drugs for CKD, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, have been developed recently, the risk of the disease remains significant, and treatment satisfaction in patients with CKD has been low.